Mechanisms of resistance to quinolones

被引:606
作者
Jacoby, GA [1 ]
机构
[1] Lahey Clin Fdn, Burlington, MA 01805 USA
关键词
D O I
10.1086/428052
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
The increased use of fluoroquinolones has led to increasing resistance to these antimicrobials, with rates of resistance that vary by both organism and geographic region. Resistance to fluoroquinolones typically arises as a result of alterations in the target enzymes ( DNA gyrase and topoisomerase IV) and of changes in drug entry and efflux. Mutations are selected first in the more susceptible target: DNA gyrase, in gram-negative bacteria, or topoisomerase IV, in gram-positive bacteria. Additional mutations in the next most susceptible target, as well as in genes controlling drug accumulation, augment resistance further, so that the most-resistant isolates have mutations in several genes. Resistance to quinolones can also be mediated by plasmids that produce the Qnr protein, which protects the quinolone targets from inhibition. Qnr plasmids have been found in the United States, Europe, and East Asia. Although Qnr by itself produces only low-level resistance, its presence facilitates the selection of higher-level resistance mutations, thus contributing to the alarming increase in resistance to quinolones.
引用
收藏
页码:S120 / S126
页数:7
相关论文
共 65 条
  • [31] Epidemiological investigation of fluoroquinolone resistance in infections due to extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae
    Lautenbach, E
    Strom, BL
    Bilker, WB
    Patel, JB
    Edelstein, PH
    Fishman, NO
    [J]. CLINICAL INFECTIOUS DISEASES, 2001, 33 (08) : 1288 - 1294
  • [32] Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections
    Lindgren, PK
    Karlsson, Å
    Hughes, D
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (10) : 3222 - 3232
  • [33] Differential regulation of the mcb and emr operons of Escherichia coli: Role of mcb in multidrug resistance
    Lomovskaya, O
    Kawai, F
    Matin, A
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1996, 40 (04) : 1050 - 1052
  • [34] Low DE, 2003, QUINOLONE ANTIMICROB, P355
  • [35] Resistance-nodulation-cell division-type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454
    Magnet, S
    Courvalin, P
    Lambert, T
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) : 3375 - 3380
  • [36] Quinolone resistance from a transferable plasmid
    Martínez-Martínez, L
    Pascual, A
    Jacoby, GA
    [J]. LANCET, 1998, 351 (9105) : 797 - 799
  • [37] Interaction of plasmid and host quinolone resistance
    Martínez-Martínez, L
    Pascual, A
    García, I
    Tran, J
    Jacoby, GA
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2003, 51 (04) : 1037 - 1039
  • [38] Intrinsic resistance of Mycobacterium smegmatis to fluoroquinolones may be influenced by new pentapeptide protein MfpA
    Montero, C
    Mateu, G
    Rodriguez, R
    Takiff, H
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (12) : 3387 - 3392
  • [39] Antibiotic resistance among gram-negative bacilli in US intensive care units - Implications for fluoroquinolone use
    Neuhauser, MM
    Weinstein, RA
    Rydman, R
    Danziger, LH
    Karam, G
    Quinn, JP
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (07): : 885 - 888
  • [40] The epidemiology of fluoroquinolone-resistant Neisseria gonorrhoeae in Hawaii, 2001
    Newman, LM
    Wang, SA
    Ohye, RG
    O'Connor, N
    Lee, MV
    Weinstock, HS
    [J]. CLINICAL INFECTIOUS DISEASES, 2004, 38 (05) : 649 - 654